Faculty Opinions recommendation of Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β3 -Adrenoceptor Agonist, in Japanese Patients with Overactive Bladder.

2017 ◽  
Author(s):  
Lori Ann Birder
Keyword(s):  
Overactive Bladder ◽  
Japanese Patients ◽  
Phase Iii ◽  
Safety And Efficacy ◽  
Adrenoceptor Agonist ◽  
Phase Iii Study

683 Randomised, double-blind, active-controlled phase III study to assess the long-term safety and efficacy of mirabegron in overactive bladder (OAB)

2012 ◽  
Vol 11 (1) ◽  
pp. e683-e683a ◽  
Author(s):  
C.R. Chapple ◽  
S. Kaplan ◽  
H.D. Mitcheson ◽  
J. Klecka ◽  
J. Cummings ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Phase Iii ◽  
Double Blind ◽  
Safety And Efficacy ◽  
Phase Iii Study

scholarly journals Long-term safety and efficacy of the novel β3-adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study

2018 ◽  
Vol 25 (7) ◽  
pp. 668-675 ◽  
Author(s):  
Masaki Yoshida ◽  
Hidehiro Kakizaki ◽  
Satoru Takahashi ◽  
Shinji Nagai ◽  
Takafumi Kurose
Keyword(s):  
Overactive Bladder ◽  
Prospective Study ◽  
Japanese Patients ◽  
Phase Iii ◽  
The Novel ◽  
Safety And Efficacy
Sign in / Sign up

Export Citation Format

Share Document